Kaitlyn M. Le

Median progression-free survival reached 24.9 months with Tukysa plus Herceptin and Perjeta versus 16.3 months with placebo plus Herceptin and Perjeta.

Epkinly plus R-CHOP lowered the risk of disease progression or death by 51% versus R-CHOP alone in patients with newly diagnosed diffuse large B-cell lymphoma.

Katie Parrinello was diagnosed with primary mediastinal B-cell lymphoma at 29, reached remission four days before turning 30 and now advocates for wig education.

A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.

After 17 and a half years with metastatic primary peritoneal cancer, a former hospital executive explains how an AI health agent helped her after discharge.

Relatives of people with BRCA1 or BRCA2 variants completed genetic testing more often when a navigator reached out directly than when they received a letter.

The FDA approval is based on the phase 3 BRUIN CLL-313 trial, in which 94% of patients responded to Jaypirca compared with 81% who received chemoimmunotherapy.

Giredestrant plus Afinitor lowered the risk of cancer worsening or death by 62% in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer.

Patients with HPV-associated oropharyngeal cancer who received 23% less radiation reported fewer swallowing, voice and dry mouth problems six months after treatment.

Heather Curley discusses her leptomeningeal disease diagnosis, joining an experimental vaccine trial and the milestones she has been able to share with her daughter.

Six years after being diagnosed with B-cell ALL at 21, William Yank opens up about the physical changes of treatment, the emotional weight of constant care and the role hope plays in his survivorship.

After two relapses, CAR T-cell therapy, immunotherapy and a stem cell transplant, William Yank is in remission, where he navigates a new reality shaped by infertility, mental health challenges and a changed sense of self.

Some patients with lymphoma show no detectable cancer by day 8 of treatment, and a lymphoma specialist explains how early testing could guide care.

She was diagnosed with stage 4 primary mediastinal B-cell lymphoma (PMBCL), a type of non-Hodgkin lymphoma that starts in the center of the chest, at 29.

Dr. David DiBardino explains how intratumoral therapy is being studied to deliver treatment directly into tumors and potentially enhance radiation in patients with locally advanced non-small cell lung cancer.

Kazia Therapeutics CEO Dr. John Friend discussed how paxalisib is being studied in HR-positive, HER2-negative breast cancer, why researchers are focusing on treatment resistance and what the ongoing clinical trial could show for patients.

Patients with colorectal cancer who walked more had less fatigue and better quality of life, regardless of how active they were at diagnosis.

After two relapses of acute lymphoblastic leukemia, Hannah Koepsell received CAR-T cell therapy. A pediatric oncologist explains why leukemia can return after treatment and how researchers are working to make CAR-T responses last longer.

Lyrfigtu was approved for adults with previously treated cholangiocarcinoma with an FGFR2 gene fusion or other rearrangement.

Researchers are studying whether combining CAR-T cell therapy with targeted drugs could help children with high-risk leukemia, including infants whose cancer may be more likely to return after treatment.

Mindfulness-based cancer recovery and Tai Chi/Qigong improved fatigue and how much pain interfered with daily life among cancer survivors experiencing distress, while Tai Chi/Qigong also improved sleep quality.

Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.

Bravnetsa is the first radioligand therapy approved through the FDA's abbreviated pathway, adding an option for adults with SSTR-positive GEP-NETs.

The investigational drug, first developed for brain cancer, is being tested to see whether it can make resistant tumors respond to treatment again.

In patients with advanced ROS1-positive lung cancer who had not previously received a ROS1-targeted drug, Jideytro also shrank tumors that had spread to the brain in all 10 evaluable patients.

An estimated 70% of patients with stage 3 lung cancer do not see their tumors respond to standard treatment. An expert explains why, and what a new approach aims to change.

Updated NCCN guidelines for multiple myeloma add dedicated recommendations for MRD testing, prefer tests that can detect one cancer cell among 1 million cells and expand when testing should occur.

Lunsumio added to Revlimid kept relapsed or refractory follicular lymphoma from worsening longer than Rituxan plus Revlimid in the phase 3 CELESTIMO trial.

Phase 2 findings on divesiran point to a potential way to control hematocrit while reducing repeated blood draws for those living with polycythemia vera, like Nona Baker.

Four of seven patients had no visible cancer on scans in early data from CONVERGE, a trial testing a tumor injection meant to boost radiation in lung cancer.